Page last updated: 2024-11-10

hirsutine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3037884
CHEMBL ID327134
MeSH IDM0115565

Synonyms (27)

Synonym
17,18-seco-3-beta-yohimban-16-carboxylic acid, 16,17-didehydro-17-methoxy-, methyl ester, (e)-
hirsutine ,
(e)-16,17-didehydro-17-methoxy-17,18-seco-3-beta-yohimban-16-carboxylic acid methyl ester
corynan-16-carboxylic acid, 16,17-didehydro-17-methoxy-, methyl ester, (3-beta,16e)-
CHEMBL327134 ,
7729-23-9
C16972
methyl (e)-2-[(2s,3r,12br)-3-ethyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate
bdbm50396011
w596of93c7 ,
unii-w596of93c7
corynan-16-carboxylic acid, 16,17-didehydro-17-methoxy-, methyl ester, (3.beta.,16e)-
17,18-seco-3.beta.-yohimban-16-carboxylic acid, 16,17-didehydro-17-methoxy-, methyl ester, (e)-
76376-57-3
indolo(2,3-a)quinolizine-2-acetic acid, 3-ethyl-1,2,3,4,6,7,12,12b-octahydro-.alpha.-(methoxymethylene)-, methyl ester, (.alpha.e,2s,3r,12br)-
AC-34492
dihydrotestosteronebenzoate
Q15614855
HY-N2193
CS-0019501
hirsutine, (3beta,16e)-isomer
MS-25915
indolo(2,3-a)quinolizine-2-acetic acid, 3-ethyl-1,2,3,4,6,7,12,12b-octahydro-alpha-(methoxymethylene)-, methyl ester, (alphae,2s,3r,12br)-
corynan-16-carboxylic acid, 16,17-didehydro-17-methoxy-, methyl ester, (3beta,16e)-
17,18-seco-3beta-yohimban-16-carboxylic acid, 16,17-didehydro-17-methoxy-, methyl ester, (e)-
DTXSID801045724
AKOS040760133

Research Excerpts

Overview

Hirsutine (HSN) is a naturally occurring indole alkaloid found in various Uncaria species. It has a multitude of therapeutic benefits.

ExcerptReferenceRelevance
"Hirsutine (HSN) is a naturally occurring indole alkaloid found in various Uncaria species and has a multitude of therapeutic benefits."( Hirsutine, an Emerging Natural Product with Promising Therapeutic Benefits: A Systematic Review.
Bappi, MH; Bhuia, MS; Chowdhury, R; Ferdous, J; Islam, MT; Mubarak, MS; Rahman, MA; Wilairatana, P, 2023
)
3.07

Effects

ExcerptReferenceRelevance
"Hirsutine has been shown to protect cardiomyocytes against hypoxic injury."( Hirsutine ameliorates myocardial ischemia-reperfusion injury through improving mitochondrial function via CaMKII pathway.
Chen, J; Chen, Q; Jiang, W; Liu, J; Pan, X; Zhang, W; Zhang, Y, 2023
)
3.07

Pharmacokinetics

ExcerptReferenceRelevance
" It was applied to the analysis of the male Sprague Dawley rat plasma samples obtained during pharmacokinetic studies of corynantheidine administered both intravenously (I."( Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies.
Avery, BA; Berthold, EC; Cerlati, O; Kamble, SH; King, TI; León, F; McCurdy, CR; McMahon, LR; Popa, R; Prentice, BM; Sharma, A, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" Absolute oral bioavailability was 49."( Bioanalytical method development and validation of corynantheidine, a kratom alkaloid, using UPLC-MS/MS, and its application to preclinical pharmacokinetic studies.
Avery, BA; Berthold, EC; Cerlati, O; Kamble, SH; King, TI; León, F; McCurdy, CR; McMahon, LR; Popa, R; Prentice, BM; Sharma, A, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
"; n = 4) in antagonizing cumulative dose-response curve for Ca2+ in the depolarized aorta strips."( Ca2+ channel blocking effects of hirsutine, an indole alkaloid from Uncaria genus, in the isolated rat aorta.
Aimi, N; Horie, S; Horiuchi, H; Sakai, S; Watanabe, K; Yano, S, 1991
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CholinesteraseHomo sapiens (human)IC50 (µMol)1.97000.00001.559910.0000AID697830
CholinesteraseEquus caballus (horse)IC50 (µMol)4.97000.00002.22149.4000AID697829
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID697829Inhibition of horse BChE by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697831Inhibition of electric eel AChE by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1599379Antiviral activity against DENV1 infected in human A549 cells after 3 days by focus reduction assay2019European journal of medicinal chemistry, Aug-15, Volume: 176Recent update on anti-dengue drug discovery.
AID697830Inhibition of human BChE by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (5.26)18.7374
1990's6 (15.79)18.2507
2000's6 (15.79)29.6817
2010's16 (42.11)24.3611
2020's8 (21.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.80 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]